Long QT syndrome (LQTS) causes sudden cardiac death due to ventricular arrhythmias such as Torsades de Pointes (TdP) or ventricular fibrillation (VF). Functional 2:1 atrioventricular block (AVB), one of the malignant forms of arrhythmias in LQTS, is most frequently observed in neonates with LQTS type 2 or 3.
| INTRODUC TI ON
Long QT syndrome (LQTS) causes sudden cardiac death due to ventricular arrhythmias such as Torsades de Pointes (TdP) or ventricular fibrillation (VF). Functional 2:1 atrioventricular block (AVB), one of the malignant forms of arrhythmias in LQTS, is most frequently observed in neonates with LQTS type 2 or 3. 1 In LQTS type 3 (LQT3), a gain-offunction mutation is observed in the SCN5A gene encoding the α-subunit of the cardiac voltage-dependent sodium channel. Mexiletine, a sodium channel blocker, is considered to be effective for patients with LQT3. 2 Intravenous mexiletine for arrhythmias is commercially available and is covered by the health insurance system in Japan. We report a neonatal LQT3 case that underwent a mexiletine infusion challenge test for the diagnosis and prediction of its efficacy.
| C A S E REP ORT
A female infant was delivered at a gestational age of 37 weeks with Genetic testing revealed an SCN5A gene mutation (Val1763Met), which is a pathogenic mutation of LQT3. 3 No mutations in the SCN5A gene were found in her parents or brother.
| D ISCUSS I ON
For an effective and safe genotype-based treatment choice, an early diagnosis is especially important in patients with lethal arrhythmias in LQTS. Mexiletine has been shown to be effective in preventing TdP and VF in LQT3. 2 The use of the lidocaine infusion test for an early diagnosis has been reported. 4 Since an oral mexiletine administration is generally chosen as the maintenance therapy for LQT3, a mexiletine infusion challenge test for a diagnosis and the prediction of the efficacy would be reasonable. Although there have been reports of mexiletine challenge tests in older children and adults, 5, 6 to the best of our knowledge, this case is the first report of an intravenous mexiletine challenge test in a neonate. According to Schwarts 5 ,
half of the daily dose of oral mexiletine should be administered Because mexiletine has minimal side effects involving prolongation of the QT interval, and also has the effect of reducing the dispersion of the repolarization and prevents TdP, the mexiletine challenge test can be performed safely with a low risk of pro-arrhythmic events in LQTS patients. 6 Mexiletine has the potential of shortening the QT interval in any type of LQTS by inhibiting the late sodium current. Theoretically, mexiletine could also be effective in many LQT2 neonates with 2:1 atrioventricular block at some level, and how to distinguish them might become a problem.
Although the optimal cutoff point of the degree of shortening of the QT interval for differentiating LQT3 from the other types of LQTS in neonates is still not clear, the degree of the shortening of the QT interval might be greater in LQT3 than LQT2. While there are some limitations, a mexiletine infusion challenge test in neonates may be useful for the detection of LQT3.
| CON CLUS ION
The mexiletine infusion challenge test was effective for the prediction of the drug efficacy and for an early diagnosis in a neonate with a malignant form of LQT3.
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